Zhang Boli, academician of the Chinese Academy of Engineering and president of Tianjin University of Traditional Chinese Medicine, said in an interview with the media recently that the epidemic of new pneumonia is difficult to stop like SARS. Interest has increased significantly. He specifically mentioned the "Lianhua Qingwen", which has attracted the attention of netizens at home and abroad: Thailand has issued a sales license for Lianhua Qingwen, Ecuador has also approved it as a drug registration and can be sold, and France is preparing to use Lianhua Qingwen Plague is a clinical study for the treatment of new coronary pneumonia.
A few days ago, Lianhua Qingwen Capsules (Granules), Jinhua Qinggan Granules and Xuebijing Injection became the first batch of new drugs approved for new pneumonia in China.
Played the role of symptomatic treatment of traditional Chinese medicine
In the fight against the New Coronary Pneumonia epidemic, Chinese medicine has played an important role, especially through the clinical screening of the "three drugs (Jinhua Qinggan Granules, Lianhua Qingwen Capsules, Xuebijing Injection) Sanfang (Qingfei Paidou Decoction , Huashi Baidu Fang, Xuanfei Baidu Fang) "has definite curative effect. "The clinical symptoms of New Coronary Pneumonia are mainly manifested as fever, cough, fatigue, etc." Professor Zhang Pinghu of Yangzhou University School of Medicine said, "Three medicines and three prescriptions" were proposed by Chinese medicine, which mainly played the role of symptomatic treatment of traditional Chinese medicine.
Zhang Pinghu introduced that Lianhua Qingwen Capsules (Granules) and Jinhua Qinggan Granules have the functions of clearing away heat and detoxifying, alleviating respiratory symptoms, but the antiviral effect is limited.
Lianhua Qingwen Capsules (granules) was developed and marketed in 2004 and is a drug against influenza. The medicine is composed of Zhang Zhongjing's "Ma Xing Shi Gan Tang" in the Han Dynasty, Wu Yintong's "Yinqiao San" in the Qing Dynasty, and Liu Fangsu's "Fangfeng Tong Sheng San" in the Jin Dynasty.
The research and development of Jinhua Qinggan Granules began in 2009 during the epidemic of influenza A. It was developed and launched in 2016. This side is mainly made from the addition and subtraction of the classic antiviral prescription Yinqiaosan. It is also a drug developed for influenza.
Both influenza virus and new coronavirus can cause lung damage
In Zhang Pinghu's view, Lianhua Qingwen Capsules (granules) and Jinhua Qinggan Granules can "cross-border" anti-epidemic disease, there are two key factors: on the one hand, the clinical symptoms of new coronary pneumonia and flu symptoms are similar, They all show similar symptoms of respiratory diseases such as fever, cough, and fatigue; on the other hand, the pathogenic mechanism of new coronary pneumonia and influenza is similar. Patients infected with severe influenza virus and new coronavirus will cause lung damage, causing a large number of inflammatory cells to accumulate in the lungs, resulting in an excessive inflammatory response that induces cytokine storms, which in turn exacerbates lung damage and causes symptoms such as acute respiratory distress and multiple organ failure.
"Because of these similarities, in the early stage of the onset of New Coronary Pneumonia, treatment with Lianhua Qingwen Capsules (Granules) and Jinhua Qinggan Granules can alleviate the above symptoms through the effects of clearing away heat and detoxifying, alleviating respiratory symptoms, and so have certain relief effects." Hu said.
Zhang Pinghu told reporters that there is currently no specific medicine for this new coronavirus pneumonia. However, even if there are special antiviral drugs targeting viral targets, they must be administered early to achieve therapeutic effects, and the curative effect on severe cases caused by such viral infections in the late stage is limited. Because in the late stage of viral infection, the host's excessive inflammatory response to viral infection plays a leading role in the occurrence and development of such diseases.
Multi-disciplinary exploration of treasures of traditional Chinese medicine
"Traditional Chinese medicine is a valuable asset formed during the long-term struggle of the people in our country." Zhang Pinghu said that the medical practice guided by the thought of syndrome differentiation and treatment of "modern cold" in ancient Chinese medicine has been a major cause of this sudden infectious disease. Has made an important contribution to prevention and control.
The clinical practice of traditional Chinese medicine shows that in the absence of specific drugs, according to the clinical characteristics of different stages in the pathogenesis of new coronary pneumonia, different localities adopt the strategy of syndrome differentiation and treatment of traditional Chinese medicine, and use traditional Chinese medicine or traditional Chinese medicine to treat new coronary pneumonia have achieved certain results. .
Relevant experts of Sinopharm Jiangyin Tianjiang Pharmaceutical Co., Ltd. said that Chinese medicine pays attention to dialectical treatment, and many prescriptions are subject to change. In recent years, the development of modernization of traditional Chinese medicine has promoted the construction of "healthy China", and traditional Chinese medicine is also going to the world. Experts suggest that due to the lack of systematic evidence-based medicine and rigorous pharmacological research, there has not yet been an anti-new coronary pneumonia prescription that has been uniformly recognized by the industry and can be widely used. Therefore, in response to this acute respiratory disease with similar clinical symptoms, the country should organize multidisciplinary interdisciplinary research, concentrate research in different fields, and dig deeper into the treasure of traditional Chinese medicine to start the Chinese business card of "Chinese medicine" as soon as possible.